CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 152 enrolled
Drug / intervention
Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00637195
NCT00637195Phase 3Completed
CompareCT.gov

Evaluation of the Immunogenicity and Safety of a Commercially Available Vaccine When Co-administered With GlaxoSmithKline Biologicals' HPV Vaccine (580299) in Healthy Female Subjects.

GlaxoSmithKline·interventional·Posted Mar 17, 2008·Updated Jan 3, 2020

In Brief

A Phase 3 clinical trial evaluating Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™) and Engerix™ for Infections, Papillomavirus and Papillomavirus Vaccines. Completed, enrolled 152 participants across 2 sites.

Detailed Summary

Infection with human papillomavirus (HPV) has been clearly established as the necessary cause of cervical cancer. The current Phase 3b study is designed to assess the immunogenicity and safety of a commercially available vaccine co-administered with GlaxoSmithKline Biologicals' HPV vaccine GSK580299 in healthy female subjects.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfections, Papillomavirus, Papillomavirus Vaccines
CountriesBelgium
Collaborators--

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 17, 2008
Enrollment StartMar 11, 2008
Primary CompletionJun 20, 2008
Study CompletionJun 18, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 18.3 years ago

Interventions

Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)biological

Intramuscular administration, 3 doses.

Engerix™biological

Intramuscular administration, 4 doses.